NASDAQ:PCSA Heatwurx (PCSA) Stock Price, News & Analysis $2.16 -0.05 (-2.08%) As of 01:02 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Heatwurx Stock (NASDAQ:PCSA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Heatwurx alerts:Sign Up Key Stats Today's Range$2.01▼$2.2150-Day Range$1.98▼$3.1852-Week Range$1.76▼$19.64Volume52,101 shsAverage Volume63,817 shsMarket Capitalization$5.95 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingHold Company Overview Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland. Read More Heatwurx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScorePCSA MarketRank™: Heatwurx scored higher than 83% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingHeatwurx has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialHeatwurx has a consensus price target of $25.00, representing about 1,057.4% upside from its current price of $2.16.Amount of Analyst CoverageHeatwurx has only been the subject of 1 research reports in the past 90 days.Read more about Heatwurx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Heatwurx is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heatwurx is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHeatwurx has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Heatwurx's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.39% of the float of Heatwurx has been sold short.Short Interest Ratio / Days to CoverHeatwurx has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Heatwurx has recently decreased by 21.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHeatwurx does not currently pay a dividend.Dividend GrowthHeatwurx does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentHeatwurx has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Heatwurx this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for PCSA on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days. Company Ownership4.4 / 5Insider TradingAcquiring Shares Cluster Insider Buying7 insiders have purchased shares of Heatwurx in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $127,058.00 in company stock, which represents 2.1390% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Heatwurx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $127,058.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders2.40% of the stock of Heatwurx is held by insiders.Percentage Held by Institutions91.93% of the stock of Heatwurx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Heatwurx's insider trading history. Receive PCSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heatwurx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PCSA Stock News HeadlinesProcessa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare ConferenceJanuary 12, 2026 | globenewswire.comProcessa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer StudyJanuary 5, 2026 | globenewswire.comHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insiders and institutional holders have been sitting on positions for years and will exit the moment shares hit the market. Lance Ippolito has identified five stocks directly positioned to benefit from the SpaceX launch and the space investing wave it triggers, without the brutal IPO volatility. These picks carry none of the hype risk and all of the tailwind.June 16 at 1:00 AM | InvestPub (Ad)Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast CancerDecember 17, 2025 | globenewswire.comProcessa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025November 5, 2025 | globenewswire.comProcessa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury StrategiesAugust 7, 2025 | globenewswire.comProcessa Pharmaceuticals Provides Portfolio and Business UpdateJuly 1, 2025 | globenewswire.comProcessa Pares Gains on Equity Offer NewsJune 17, 2025 | marketwatch.comSee More Headlines PCSA Stock Analysis - Frequently Asked Questions How have PCSA shares performed this year? Heatwurx's stock was trading at $2.88 at the beginning of the year. Since then, PCSA shares have decreased by 25.0% and is now trading at $2.16. How were Heatwurx's earnings last quarter? Heatwurx Inc. (NASDAQ:PCSA) issued its quarterly earnings data on Thursday, November, 6th. The company reported ($1.75) EPS for the quarter, topping the consensus estimate of ($2.00) by $0.25. When did Heatwurx's stock split? Heatwurx shares reverse split on the morning of Wednesday, December 17th 2025.The 1-25 reverse split was announced on Monday, December 15th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 16th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Heatwurx? Shares of PCSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Heatwurx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Heatwurx investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL) and Builders FirstSource (BLDR). Company Calendar Last Earnings11/06/2025Today6/16/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 PCSA's financial health is in the Yellow zone, according to TradeSmith. PCSA has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PCSA CIK1533743 Webwww.processapharmaceuticals.com Phone(443) 776-3133Fax443-288-4420Employees20Year Founded2017Price Target and Rating Average Price Target for Heatwurx$25.00 High Price Target$25.00 Low Price Target$25.00 Potential Upside/Downside+1,055.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($9.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.56 million Net MarginsN/A Pretax MarginN/A Return on Equity-281.31% Return on Assets-200.80% Debt Debt-to-Equity RatioN/A Current Ratio0.98 Quick Ratio0.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book0.88Miscellaneous Outstanding Shares2,750,000Free Float2,684,000Market Cap$5.95 million OptionableNot Optionable Beta1.00 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PCSA) was last updated on 6/16/2026 by MarketBeat.com Staff. From Our PartnersHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredBUY THIS: Claim a backdoor stake in SpaceXThere may be a way to claim pre-IPO exposure to SpaceX before it ever hits public markets - using a simple tra...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heatwurx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heatwurx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
